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ABSTRACT 
 
DRUG UTILIZATION STUDY OF DIURETICS 
IN HEPATIC CIRRHOSIS PATIENT WITH ASCITES  
(Studied in Inpatient Rooms of Internal Medicine Installation  
RSUD Dr. Soetomo Surabaya) 
 
 
LAILY SOFIA ADIBA 
 
 
Cirrhosis is an advanced stage of liver fibrosis. Ascites is the 
most common complication of cirrhosis. Diuretics (spironolactone with 
or without furosemide) are the first-line treatment of patients with 
cirrhosis and ascites. The purpose of this study is to identify the profile 
of diuretic drugs for hepatic cirrhosis patient with ascites, and the 
possibility of Drug Related Problem (DRP) in diuretic therapy for 
hepatic cirrhosis patient with ascites at RSUD Dr. Soetomo Surabaya. 
Data was collected crossectionally with non-random and time 
limited sampling method in the period of 22 March until 22 June 2016 in 
inpatient rooms of Internal Medicine Installation RSUD Dr. Soetomo 
Surabaya. The inclusion criteria were all hepatic cirrhosis inpatient with 
ascites complication ongoing diuretic therapy for 3 days or more. This 
methodology has been approved by ethics committee of RSUD Dr. 
Soetomo Surabaya. 
The results of observational study on 34 patients showed that 
the diuretic profile that used in this study were spironolactone 
monotherapy (32,4%), furosemide monotherapy (14,7%), and 
combination of spironolactone and furosemide (73,5%). Spironolactone 
mostly used orally with 1-3 x 25-300 mg daily dose, while furosemide 
mostly used IV with 1-4 x 10-120 mg daily dose. Drug Related Problem 
(DRP) observed in this study were adverse drug reaction such as 
hyponatremia (32,4%), hypokalemia (17,7%), and hyperuricemia (2,9%) 
due to furosemide, and hyperkalemia (5,9%) due to spironolactone; 
potential drug interaction in the use of furosemide-digoxin (2,9%), 
spironolactone-digoxin (2,9%), spironolactone-ASA (2,9%), and 
spironolactone- potassium supplements (44,1%). Actual drug interaction 
was not found in this study. 
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